Systemic deficiency of GM1 ganglioside in Parkinson ’s disease tissues and its relation to the disease etiology

AbstractFollowing our initial reports on subnormal levels of GM1 in the substantia nigra and occipital cortex of Parkinson ’s disease (PD) patients, we have examined additional tissues from such patients and found these are also deficient in the ganglioside. These include innervated tissues intimately involved in PD pathology such as colon, heart and others, somewhat less intimately involved, such as skin and fibrobla sts. Finally, we have analyzed GM1 in peripheral blood mononuclear cells, a type of tissue apparently with no direct innervation, and found those too to be deficient in GM1. Those patients were all afflicted with the sporadic form of PD (sPD), and we therefore conclude that systemic deficiency of GM 1 is a characteristic of this major type of PD. Age is one factor in GM1 decline but is not sufficient; additional GM1 suppressive factors are involved in producing sPD. We discuss these and why GM1 replacement offers promise as a disease-altering therapy.

Source: Glycoconjugate Journal - January 1, 2022 Category: Biochemistry Source Type: research